 |
 |
Advances in the Prevention of VTE in Orthopedic Surgery Patients: Current and Emerging Therapies
Release Date: November-06-09
Credit Expiration Date: November-06-10
|
|
|
|
 |
 |
|
Medical Communications Media, Inc. |
|
|
|
 |
|
|
| This program has been designed for orthopedic surgeons, hospitalists, hospital pharmacists, orthopedic surgery assistants, and nurses. |
|
|
|
 |
|
|
|
|
|
 |
|
|
|
|
|
 |
|
|
THIS ACTIVITY WAS ORIGINALLY PRESENTED AS A LIVE GRAND ROUNDS SERIES BEGINNING ON APRIL 1, 2009. IF YOU EARNED CME/CE CREDIT FOR A GRAND ROUNDS PRESENTATION YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE RELEASE.
Venous thromboembolism (VTE) is the most common preventable cause of hospital death in the United States, and patients undergoing major orthopedic surgery (e.g., hip or knee arthroplasty) are among those at highest risk. Guidelines focusing on prevention of VTE in orthopedic surgery were published by the American College of Chest Physicians (ACCP) in 2008, and on the prevention of symptomatic pulmonary embolism (PE) by the American Academy of Orthopedic Surgeons (AAOS) in 2007. Despite the availability of these evidence-based guidelines, many barriers to implementation of appropriate VTE prophylaxis remain.
Findings from recent clinical research can provide clinicians with clarification about the optimal current and emerging prophylactic strategies. Efforts to assess VTE risk and apply existing evidence-based guidelines for VTE prophylaxis in orthopedic surgery patients can improve patient care and outcomes.
|
|
|
|
 |
|
|
|
|
|
 |
|
|
Clifford W. Colwell, JR., MD
Medical Director, Shiley Center for Orthopaedic Research and Education
Scripps Clinic
La Jolla, California
|
|
|
|
 |
|
|
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Colwell discloses that he has served as a consultant for Bayer HealthCare, and has conducted contracted research for Bayer HealthCare, Boehringer Ingelheim, and Medical Compression Systems Ltd.
|
|
|
|
 |
|
|
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
Pharmacists: AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. AKH Inc. approves this knowledge-based activity for 0.75 contact hour (0.075 CEU). UAN 077-9999-09-057-H01-P. Initial release date: April 1, 2009.
Nurses: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
AKH Inc. designates this educational activity for 0.75 contact hour (0.075 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.
Credit is awarded to participants who view the presentation and score 70% or better on the post-test. |
|
|
|
|
|
 |
|
|
This activity is supported by an educational grant from Ortho-McNeil, Inc., Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil-Janssen Scientific Affairs, LLC. |
|
|
|
|
|
 |
|
|
|
|
|
 |
|
|
| This educational activity may contain discussion of published and/or investigational uses of pharmacologic agents. Some uses may not have been approved by the FDA. The faculty has disclosed discussion of off-label use during the presentation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. |
|
|
| |
